Norway· NO-ID_4B51A81A-19C7-42AF-AF3E-74F1C01408D6
Tezspire
A tezepelumab product containing tezepelumab, registered in Norway by AstraZeneca AB (2). The same ATC class is registered in 16 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Tezepelumab is registered in 16 of 19 countries.
Countries holding a registration under ATC R03DX11 (tezepelumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 10 of them publish a price we can compare per daily dose
Tezepelumab · ATC R03DX11
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tezepelumab costs, country by country.
Normalised to the WHO defined daily dose (7.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tezepelumab · price per daily dose (7.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$48.28
The record
At a glance
FEST (Norway)- Active substance
- Tezepelumab
- Manufacturer
- AstraZeneca AB (2)
- Country
- Norway (NO)
- ATC code
- R03DX11
- ATC class
- Tezepelumab
- Defined daily dose
- 7.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_4B51A81A-19C7-42AF-AF3E-74F1C01408D6
- no_varenummer0418111.91NOK 15053.4
- gtin5000456073363
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tezepelumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTEZSPIREAstraZeneca AB, Södertälje
- SpainTEZSPIRE 210 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAAstrazeneca Ab
- BelgiumTezspire 210 mgAstraZeneca
- IcelandTezspireAstraZeneca AB*
- SwedenTezspire 210 mg Injektionsvätska, lösning i förfylld injektionspennaAstraZeneca AB
- PolandTezspireAstraZeneca AB
- United StatesTEZSPIREAmgen Inc
- SwitzerlandTezspire 110 mg/ml, Injektionslösung in einem FertigpenAstraZeneca AG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Tezspire
- Liechtenstein · Tezspire
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7d84c955-437f-49e1-8ca7-410041b47427 GET /v1/drugs/7d84c955-437f-49e1-8ca7-410041b47427?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning i ferdigfylt sprøyte",
"source": "fest",
"status": "A",
"atc_name": "Tezepelumab",
"merkevare_id": "ID_4B51A81A-19C7-42AF-AF3E-74F1C01408D6",
"name_form_strength": "Tezspire inj, oppl 210 mg/sprøyte",
"prescription_group": "C"
}See everything about tezepelumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.